04 March 2021
March 4, 2021, Moscow – R&D Center NovaMedica Innotech (subsidiary of the pharmaceutical company NovaMedica, investment project of RUSNANO) announced release of the first commercial batch of the anti-COVID drug Avifavir® under the partnership with Kromis LLC, joint venture of the Russian Direct Investment Fund (RDIF) and the company ChemRar. NovaMedica Innotech will manufacture 100,000 units of Avifavir per month.
«Technology transfer was done efficiently and in the shortest time possible thanks to dedicated efforts of the R&D Department team and the suitable profile of the manufacturing equipment”, says the Director General of the Technological Center NovaMedica Innotech Alexander Rudko. “The first commercial batch of the product is already available for shipment».
Production of Avifavir tablets is done at GMP-certified manufacturing sites. All procedures of the pharmaceutical quality system at the Technological Center NovaMedica Innotech ensure high quality of its products. Quality control is performed at each stage of the manufacturing process, which allows assessing conformity of the products to the requirements of specifications and regulatory documents.
Information about the Company:
NovaMedica Innotech (100% subsidiary of NovaMedica, project of Rusnano, Skolkovo resident) is a rapidly developing Russian pharmaceutical R&D center created in April 2017 in Technopolis Moscow. NovaMedica Innotech specializes in development, implementation and manufacturing of innovative, competitive and effective drug products and provides a full range of services in the pharmaceutical market in accordance with the Russian and EAEU GMP requirements. The company has unique research and manufacturing equipment that allows resolving objectives related to modification of pharmacological properties of drug products, changing their bioavailability and other characteristics of active ingredients or combining several active ingredients in one dosage form, and carrying out their commercial manufacturing at the company’s own capacities. A large part of the technologies used by the company have no equivalents in the Russian pharmaceutical industry at the moment.
Manufacturing and laboratory capacities of the R&D center allow upscaling technological processes, transferring technologies, producing samples for clinical trials and ensuring commercial manufacturing of solid dosage forms.
Contacts for mass media: Tatiana Albaut , +79175451241
Avifavir® (INN: Favipiravir) is the first drug in the world with the active ingredient Favipiravir registered for the treatment of the coronavirus infection. In May 2020, it received a temporary and in November 2020, a permanent marketing authorization from the Russian Ministry of Health, and a permit for use in out-patient care. The decision was made based on positive results of clinical trials in Russia, which confirmed the drug’s ability to block the coronavirus replication mechanism, alleviate symptoms and reduce disease time by half compared to standard treatment. Avifavir is included in the methodological recommendations of the Ministry of Health for prevention, diagnostics and treatment of the new coronavirus infection.
In November 2020, the Russian Direct Investment Fund (RDIF) announced (https://rdif.ru/fullNews/5975/) that the drug will be provided free-of-charge under the obligatory medical insurance program to the Russian patients treated for coronavirus at healthcare facilities pursuant to the Government order on financing of purchase of drug products for the treatment of patients with the new coronavirus infection treated in the out-patient format. Avifavir is also supplied to 15 other countries.Print
16 April 2021
16 April 2021
15 April 2021
15 April 2021